A Retrospective Analysis of Factors Affecting Treatment Outcome and Patient Experience in Elderly Head and Neck Cancer Patients: The Odette Cancer Centre Experience

2014 ◽  
Vol 45 (2) ◽  
pp. 169-170
Author(s):  
Nikolaus Gregor ◽  
Angela Turner ◽  
Justin Lee
2015 ◽  
Vol 26 ◽  
pp. vii136
Author(s):  
Hayato Kamata ◽  
Shinya Suzuki ◽  
Kiwako Ikegawa ◽  
Hisanaga Nomura ◽  
Tomohiro Enokida ◽  
...  

2020 ◽  
Vol 58 (10) ◽  
pp. e157-e158
Author(s):  
David McGoldrick ◽  
Aghiad Yassin Alsabbagh ◽  
Laura Pettit ◽  
Moinuddin Shaikh ◽  
Sunil Bhatia

2020 ◽  
Author(s):  
Ines Lardinois ◽  
Didier Dequanter ◽  
Jérôme R. Lechien ◽  
Cyril Bouland ◽  
Rokneddine Javadian ◽  
...  

2020 ◽  
Vol 11 (4) ◽  
pp. 769-777
Author(s):  
Abhishek Kandwal ◽  
Sunil Saini ◽  
Mustaq Ahmad ◽  
Vipul Nautiyal ◽  
Manisa Pattanayak ◽  
...  

2011 ◽  
Vol 106 (5) ◽  
pp. 290-296 ◽  
Author(s):  
Aravind Buddula ◽  
Daniel A. Assad ◽  
Thomas J. Salinas ◽  
Yolanda I. Garces ◽  
John E. Volz ◽  
...  

2021 ◽  
Author(s):  
Hundo Cho ◽  
Seok Yun Kang ◽  
Hyun Woo Lee ◽  
Yong Won Choi ◽  
Tae-Hwan Kim ◽  
...  

Abstract Background The risk of thromboembolic events (TEE) in cancer patients, especially those receiving cisplatin-based chemotherapy, is higher than that of general population. Methods The study investigated the incidence of TEE in 257 head and neck (H&N) cancer patients, during or within 6 months of completion of concurrent chemoradiotherapy (CCRT) with cisplatin, and analyzed factors affecting TEE occurrence. Results TEE occurred in 5 patients, an incidence rate of 1.9%. Khorana score was the only factor associated with TEE occurrence (p = 0.010). Conclusions The incidence of TEE in H&N cancer patients who underwent CCRT with cisplatin was relatively low when compared to other types of cancer. However, patients with a high Khorana score require more careful surveillance for possible TEE occurrence.


Sign in / Sign up

Export Citation Format

Share Document